Jeroen van de Pol

154 Chapter 5.2 [17] Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360-1. [18] Reed Johnson F, Lancsar E, Marshall D et al. Constructing experimental designs for discrete choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3–13. [19] Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–15. [20] Heringa M, Floor-Schreudering A, Wouters H et al. Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis. Drug Saf. 2018;41(2):179-89. [21] AMP Onderzoek & Advies in de zorg. URL: www.ampnet.nl [22] Schaffer EM, Gonzalez JM, Wheeler SB et al. Promoting HIV Testing by Men: A Discrete Choice Experiment to Elicit Preferences and Predict Uptake of Community-based Testing in Uganda. Appl Health Econ Health Policy. 2020;18(3):413-32. [23] PorteousT,RyanM,BondCetal.ManagingMinorAilments; ThePublic'sPreferences forAttributes of Community Pharmacies. A Discrete Choice Experiment. PLoS One. 2016;11(3):e0152257. [24] Naik-Panvelkar P, Armour C, Rose J et al. Patients' value of asthma services in Australian pharmacies: the way ahead for asthma care. J Asthma. 2012;49(3):310–6. [25] Sawtooth Software. The CBC Latent Class Technical Paper (version 3). 2004. URL: https:// sawtoothsoftware.com/advanced-analytical-tools/cbc-latent-class [26] Steckowych K, Smith M, Spiggle S et al. Building the Case: Changing Consumer Perceptions of the Value of Expanded Community Pharmacist Services. J Pharm Pract. 2019;32(6):637–47. [27] Canadian Pharmacist association. Pharmacists’ Scope of Practice in Canada. January 2020. URL: https://www.pharmacists.ca/pharmacy-in-canada/scope-of-practice-canada/ [28] Famiyeh IM, McCarthy L. Pharmacist prescribing: A scoping review about the views and experiences of patients and the public. Res Social Adm Pharm. 2017;13(1):1–16. [29] Moaddeb J, Mills R, Haga SB. Community pharmacists' experience with pharmacogenetic testing. J Am Pharm Assoc (2003). 2015;55(6):587–94. [30] Buss VH, Deeks LS, Shield A et al. Analytical quality and effectiveness of point-of-care testing in community pharmacies: A systematic literature review. Res Social Adm Pharm. 2019;15(5):483–495. [31] Hohmeier KC, Loomis B, Gatwood J. Consumer perceptions of and willingness-to-pay for point- of-care testing services in the community pharmacy. Res Social Adm Pharm. 2018;14(4):360–6. [32] Koster ES, Philbert D, Bouvy ML. Impact of the COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies. Res Social Adm Pharm 2021;17(1):2002-4.